Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection

Not Applicable

Not yet recruiting

Interventions: Drug: Clarithromycin 500 mg
Drug: Levofloxacin 500 mg
Drug: Amoxicillin 1 g
Drug: Omeprazole 40 mg
Drug: Vonoprazan 20 mg

Brief Summary: Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations.

This study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice.

Detailed Description: Currently, there are numerous H. pylori eradication regimens, but opinions vary regarding the effectiveness of those based on P-CAB or PPI. Zhang et al. 4 concluded that the P-CAB-based triple regimen was superior to the PPI-based regimen, whereas Du et al.5 suggested that a vonoprazan and amoxicillin duo regimen may be the preferred first-line option for H. pylori eradication in clinical practice. However, due to limited evidence, the efficacy of various H. pylori eradication regimens using tegoprazan or vonoprazan could not be compared.

Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations.

This study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice.

Objective: To compare the efficacy of vonoprazan-based H. pylori eradication therapy with conventional proton pump inhibitors based therapy.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

patients under 12 years old.
Patients who have penicillin allergy.
Patients who have underlying dysrhythmia forbidding the use of macrolide -. Patient who have hypersensitivity to any of these antibiotics or proton pump inhibitors.

Arm && Interventions

Group	Intervention	Description
First-Line Therapy with Omeprazole	Clarithromycin 500 mg	-
First-Line Therapy with Omeprazole	Amoxicillin 1 g	-
First-Line Therapy with Omeprazole	Omeprazole 40 mg	-
First-Line Therapy with Vonoprazan	Clarithromycin 500 mg	-
First-Line Therapy with Vonoprazan	Amoxicillin 1 g	-
First-Line Therapy with Vonoprazan	Vonoprazan 20 mg	-
Second-Line Therapy with Omeprazole	Levofloxacin 500 mg	-
Second-Line Therapy with Omeprazole	Amoxicillin 1 g	-
Second-Line Therapy with Omeprazole	Omeprazole 40 mg	-
Second-Line Therapy with Vonoprazan	Levofloxacin 500 mg	Participants receiving second-line therapy (levofloxacin + amoxicillin) with vonoprazan as the acid suppressant.
Second-Line Therapy with Vonoprazan	Amoxicillin 1 g	Participants receiving second-line therapy (levofloxacin + amoxicillin) with vonoprazan as the acid suppressant.
Second-Line Therapy with Vonoprazan	Vonoprazan 20 mg	Participants receiving second-line therapy (levofloxacin + amoxicillin) with vonoprazan as the acid suppressant.

Primary Outcome Measures

Name	Time	Method
H. pylori Eradication Rate	4-6 weeks after completion of therapy	Proportion of participants with successful eradication of Helicobacter pylori infection, confirmed by a negative stool antigen test.

Secondary Outcome Measures

Name	Time	Method
Incidence of Adverse Events	During the 6-week treatment and follow-up period	Number and type of treatment-related adverse effects (e.g., nausea, diarrhea, headache, abdominal discomfort) reported by participants during or after therapy

Locations (1): Rehman Medical Institue
🇵🇰
Peshawar, K, Pakistan
Rehman Medical Institue
🇵🇰Peshawar, K, Pakistan